http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103271916-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bc04cbe597b38449dcb758bfddb8f9a0 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 |
| filingDate | 2013-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103271916-A |
| titleOfInvention | Applications of Myriberine A in preparing drugs for treating prostate cancer |
| abstract | The invention discloses applications of Myriberine A in preparing drugs for treating prostate cancer, belonging to the technical field of new applications of drugs. Detected through in-vitro MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) anti-tumor activity evaluation, Myriberine A also has remarkable inhibition action on the growth of human prostate cancer cell strains ALVA, gpc-1, 9L-B and Du145. Therefore, Myriberine A can be used for preparing drugs for resisting prostate cancer, and has good development and application prospects. The applications of Myriberine A in preparing drugs for treating prostate cancer are disclosed for the first time, and the inhibitory activity to the prostate cancer is unexpectedly strong. |
| priorityDate | 2013-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 18.